BOLOGNA BOLOGNA, ROYAL HOTEL CARLTON. Bologna, Royal Hotel Carlton October 1-3, 2018 PRELIMINARY PROGRAM

Transcription

1 PRELIMINARY PROGRAM President: Pier Luigi Zinzani Co-President: Michele Cavo Honorary President: Sante Tura Bologna, Royal Hotel Carlton October 1-3, 2018 BOLOGNA BOLOGNA, ROYAL HOTEL CARLTON

2 Auspices FACULTY ALMA MATER STUDIORUM UNIVERSITÀ DEGLI STUDI DI BOLOGNA REGIONE EMILIA-ROMAGNA AZIENDA OSPEDALIERO-UNIVERSITARIA DI BOLOGNA AIL ASSOCIAZIONE ITALIANA CONTRO LE LEUCEMIE - LINFOMI E MIELOMA SEZIONE DI BOLOGNA SIE - SOCIETÀ ITALIANA DI EMATOLOGIA Ranjana Advani Stanford, USA Stephen M. Ansell Rochester, USA Andrea Artoni Milan, Italy Michele Baccarani Bologna, Italy Andrea Bacigalupo Rome, Italy Nizar J. Bahlis Calgary, Canada Ivan Borrello Baltimore, USA Massimo Breccia Rome, Italy Tim H. Brummendorf Aachen, Germany Lars Bullinger Berlin, Germany Christian Buske Ulm, Germany John Byrd Columbus, USA Michele Cavo Bologna, Italy Robert Chen Duarte, USA Bruce D. Cheson Washington, USA Paolo Corradini Milan, Italy Jorge E. Cortes Houston, USA Antonio Cuneo Ferrara, Italy Ian Flinn Nashville, USA Robin Foà Rome, Italy Andres Forero-Torres Birmingham, USA Nathan H. Fowler Houston, USA Francesco Galimi Thousand Oaks, USA Leo I Gordon Chicago, USA John Gribben London, United Kingdom Claire Harrison London, United Kingdom Elias Jabbour Houston, USA Joseph G. Jurcic New York, USA Wojciech Jurczak Kraków, Poland Jean Jacques Kiladjian Paris, France Arne Kolstad Oslo, Norway Marina Konopleva Houston, USA Shaji K. Kumar Rochester, USA John Kuruvilla Toronto, Canada Mark Levis Baltimore, USA Giovanni Martinelli Meldola-FC, Italy John O. Mascarenhas New York, USA Anthony R. Mato New York, USA Philippe Moreau Nantes, France Alison J. Moskowitz New York, USA Craig H. Moskowitz New York, USA Sattva S. Neelapu Houston, USA Susan M. O Brien Irvine, USA Owen A. O Connor New York, USA Michinori Ogura Kasugai City, Japan Fabrizio Pane Naples, Italy Cristina Papayannidis Bologna, Italy Francesco Passamonti Varese, Italy Ruth Pettengell London, United Kingdom Vincent Ribrag Villejuif, France Paul G. Richardson Boston, USA Davide Rossi Bellinzona, Switzerland Gianantonio Rosti Bologna, Italy Simon Rule Plymouth, United Kingdom Roland Schmitz Bethesda, USA Laurie H. Sehn Vancouver, Canada John F. Seymour Melbourne, Australia Michele Spina Aviano, Italy Juan Louis Steegmann Madrid, Spain Constantine Tam Melbourne, Australia Alessandro M. Vannucchi Florence, Italy Ravi Vij St. Louis, USA Umberto Vitolo Turin, Italy Anas Younes New York, USA Andrew D. Zelenez New York, USA Pier Luigi Zinzani Bologna, Italy 1

3 Monday, October 1, a.m. Welcome and Introduction Three recent impressive stories Chairman: P. Corradini 9.15 a.m. Checkpoint inhibitors - A. Younes 9.40 a.m. Daratumumab - M. Cavo a.m. CAR T-cells - S.S. Neelapu Session I: Classical Ph1-neg myeloproliferative neoplasms Chairmen: F. Passamonti, A.M. Vannucchi a.m. Status of the art of treatment - C. Harrison a.m. Ruxolitinib in myelofibrosis - F. Passamonti a.m. Ruxolitinib in polycitemia vera - A.M. Vannucchi a.m. Interferons in MPNs - J.J. Kiladjian a.m. New drugs and combination therapy - J.O. Mascarenhas p.m. Allotransplant in myelofibrosis - A. Bacigalupo p.m. Lunch Session II: Hodgkin s lymphoma Chairmen: A. Younes, P.L. Zinzani 1.30 p.m. Status of the art of treatment - A. Younes 1.50 p.m. Nivolumab - A. Younes 2.05 p.m. Pembrolizumab - R. Chen 2.20 p.m. Brentuximab vedotin - A.J. Moskowitz 2.35 p.m. New Combo-steps - S.M. Ansell Focus on: Prognostic factor and prediction of response in lymphoma Chairman: B.D Cheson 2.55 p.m. Molecular predictors of response - R. Schmitz 3.15 p.m. Can we use imaging to predict response? - C.H. Moskowitz 3.35 p.m. Role of circulating tumor DNA in response prediction and assessment of clonal evolution - D. Rossi SESSION III: Acute leukemia Chairmen: M. Levis, G. Martinelli 4.00 p.m. Status of the art: from genomic knowledge to target therapy in leukemias - L. Bullinger 4.20 p.m. Gliteritinib - M. Levis 4.35 p.m. Quizartinib - J.E. Cortes 4.50 p.m. SY J.G. Jurcic 5.05 p.m. Inotuzumab in ALL - E. Jabbour 5.20 p.m. Venetoclax - M. Konopleva 5.35 p.m. Idasanutlin - C. Papayannidis 5.50 p.m. Ponatinib - E. Jabbour 6.05 p.m. MCL1 inhibitors - F. Galimi 6.20 p.m. Blinatumumab in Ph+ and Ph neg ALL - R. Foà 3

4 Tuesday, October 2, 2018 SESSION IV: Non-Hodgkin s lymphoma (I) Chairmen: S.M. Ansell, O.A. O Connor 8.30 a.m. Status of the art of treatment - S.M. Ansell 8.50 a.m. Obinutuzumab - L.H. Sehn 9.05 a.m. MOR208 - W. Jurczak 9.15 a.m. Polatuzumab - R. Advani 9.30 a.m. Mogamulizumab - M. Ogura 9.45 a.m. CC V. Ribrag a.m. EDO-S101 - O.A. O Connor a.m. Selinexor - J. Kuruvilla a.m. Pixantrone - R. Pettengell a.m. Coffee break Session V: Chronic Lymphocitic Leukemia Chairmen: A. Cuneo, R. Foà a.m. Status of the art of management - S.M. O Brien a.m. Ibrutinib - J. Byrd a.m. Idelalisib - A.D. Zelenez p.m. Venetoclax - J. Seymour p.m. Acalabrutinib - J. Byrd p.m. BGB C. Tam p.m. TGR J. Gribben Focus on: the old, the new and the future in the same drug Chairman: M. Spina 2.15 p.m. Bendamustine - B.D. Cheson 2.35 p.m. Lenalidomide - N.H. Fowler 2.55 p.m. Rituximab biosimilars - C. Buske 3.15 p.m. Umbralisib (TGR-1202) - A.R. Mato SESSION VI: Non-Hodgkin s lymphoma (II) Chairmen: N.H. Fowler, U. Vitolo 3.50 p.m. BGB C. Tam 4.05 p.m. Venetoclax - S. Rule 4.20 p.m. Idelalisib - S.M. Ansell 4.35 p.m. Umbralisib - O.A. O Connor 4.50 p.m. Copanlisib - P.L. Zinzani 5.05 p.m. Duvelisib - I. Flinn 5.20 p.m. INCB A. Forero-Torres 5.35 p.m. ME A. Zelenetz 5.50 p.m. Acalabrutinib - S. Rule 6.05 p.m. Tazemetostat - V. Ribrag 6.20 p.m. TAK L.I. Gordon 6.35 p.m. Betalutin - A. Kolstad 1.15 p.m. Lunch 4 5

5 Wednesday, October 3, a.m. Lecture Thrombotic thrombocytopenic purpura: a look at the future - A. Artoni SESSION VII: Multiple myeloma Chairmen: M. Cavo, P.G. Richardson 8.50 a.m. New proteasome inhibitors (Oprozomib, Marizomib) - P.G. Richardson 9.10 a.m. Selinexor - N. Bahlis 9.30 a.m. Venetoclax - P. Moreau 9.50 a.m. Monoclonal antibodies: Isatuximab, MOR202 - S.K. Kumar a.m. Monoclonal antibodies and BTKs: anti-pd-1/pdl-1, Ibrutinib - R. Vij SESSION VIII: Chronic myeloid leukemia Chairmen: F. Pane, G. Rosti a.m. Bosutinib - T.H. Brummendorf a.m. CAR-T and other immunotherapies - I. Borrello a.m. Imatinib, nilotinib and dasatinib frontline: which and why? - J.L. Steegmann a.m. ABI001 and combination - M. Breccia a.m. Ponatinib - M. Baccarani p.m. Treatment free remission - G. Rosti p.m. Conclusions and Arrivederci 6 7

6 GENERAL INFORMATION MEETING VENUE Royal Hotel Carlton Via Montebello, Bologna, Italy Phone Fax OFFICIAL LANGUAGE English REGISTRATION FEE Euro 400,00 (Italian VAT included) The registration fee includes: conference kit, participation in the scientific sessions, attendance certificate, coffee breaks, lunch, slides of the meeting. BADGE All registered participants, speakers and exhibitors will be given a badge which they must wear to be admitted to the scientific sessions. ATTENDANCE CERTIFICATE A certificate will be given to all participants at the end of the meeting. ITALIAN CME CREDITS A request for Italian CME credits have been made as follows: - Provider Studio ER Congressi SRL: ID No. 6 CME credits for physicians (disciplines: Allergology and Clinical Immunology, Dermatology and Venereology, Hematology, Oncology, Pathological Anatomy, Clinical Biochemistry, Clinical Pathology), biologists and chemists. - Educational objective: guidelines-protocols-procedures. EUROPEAN CME CREDITS The program of the New Drugs in Hematology has been reviewed and approved for CME accreditation by the European Board for Accreditation in Hematology (EBAH), an independent accreditation body endorsed by EHA. The EBAH Unit has approved this educational activity for no. 22 CME credits for Physicians, biologists and chimists. To request credits, please fill out the form and return it to the registration desk at the end of the meeting. We remind you that it is necessary to have an EBAH-CME account in order to claim for credits. Attendees can create an EBAH-CME account registering on the website: even on site. CHANGES Parts of the program may be changed without notice. 8

7 Scientific Secretariat Pier Luigi Zinzani Istituto di Ematologia Lorenzo e Ariosto Seràgnoli Via Massarenti, Bologna, Italy Phone Fax pierluigi.zinzani@unibo.it Organizing Secretariat Studio E.R. Congressi Via Marconi, Bologna, Italy Phone Fax ercongressi@ercongressi.it struchel.com